2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1671 Genetic dissection of cdks reveals distinct roles in venetoclax response and identifies CDK2 as a therapeutic vulnerability in AML

Melissa Laura Stewart, PhD, Jessica Gibbs2, Andy Kaempf, MS3, Yaseen Arifin4, Jeffrey Tyner, PhD5
1 Oregon Health and Science University, Portland, United States
2 Oregon Health and Science University, Portland, Oregon, United States
3 Oregon Health and Science University, Portland, Oregon, United States
4 Oregon Health and Science University, Portland, Oregon, United States
5 Oregon Health and Science University, Portland, Oregon, United States

Introduction:  The BCL2 inhibitor venetoclax (ven), in combination with azacytidine, is the current standard of care treatment for Acute Myeloid Leukemia (AML) patients who are elderly and unfit to receive standard chemotherapy. Recent studies from our lab showed that cyclin dependent kinase (CDK)4/6 inhibition acts synergistically with venetoclax in AML (Eide et al. 2023, Stewart et al. 2026). CDK4/6 inhibitors are widely used in the treatment of breast cancer and their use in AML is being explored, however, the distinct roles of individual CDKs in AML and in relation to venetoclax response have not been thoroughly investigated.

Previously, our lab performed genome-wide CRISPR screening in AML cell lines and identified CDK2 and its partner, CyclinE (CCNE1), as genetic vulnerabilities in RB1 KO cells (Stewart et al. 2026), which are known to be resistant to CDK4/6 inhibition in breast cancer patients (Palafox et al. 2022), suggesting distinct roles of CDKs in AML.  CDK4/6 inhibitors are generally well tolerated in the clinical setting, but they commonly cause neutropenia and other forms of myelosuppression due to the unique role of CDK6 in the proliferation of hematopoietic progenitors in the bone marrow (Stanciu et al. 2023). Therefore, efforts to develop CDK4 selective inhibitors and drugs that target other CDKs are underway. Many of these drugs are in early clinical trials for breast cancer patients, however their use in the treatment of AML has not been evaluated.

Methods: RNA-sequencing data and ex vivo venetoclax drug sensitivity data from our Beat AML cohort were integrated to evaluate the association between CDK6 mRNA expression and veneoclax response. To evaluate the role of CDK inhibition in AML, we treated primary AML samples and ven-sensitive and resistant AML cell lines with a panel of CDK inhibitors and assessed drug sensitivity alone and in combination with ven. To define the contribution of individual CDKs to ven response, we generated CDK knockout (KO) AML cell lines using CRISPR-Cas9 mediated lentiviral transduction and evaluated drug response to ven. Seven-point dose response assays were performed to determine the IC50 and area under the curve (AUC) for each inhibitor. Immunoblot was used to show efficient knockdown of CDK genes and to examine apoptotic proteins of the BCL2 family in CDK KO cell lines. RNA-seq was performed on CDK6 KO cells to determine changes in transcriptional programming and differentially expressed genes were used for pathway analysis using the Reactome database.

Results: In AML patient samples, low expression of CDK6 mRNA correlated with higher venetoclax AUC values (k=-36.77,  r = -0.60) suggesting decreased response to ven with loss of CDK6. CRISPR-mediated genetic loss of CDK6, but not CDK4 or CDK2, decreased sensitivity to ven in AML cell lines. Protein levels of the venetoclax target BCL2 were significantly decreased in CDK6 KO AML cells but not in CDK4 or CDK2 KO cells, suggesting downregulation of BCL2 in the context of CDK6 loss could potentially account for the decreased ven response. Consistent with this, CDK6 mRNA expression was positively correlated with BCL2 mRNA expression in AML patient samples as well (r = 0.5325, p <0.0001, n=708 samples). RNA-seq data from CDK6 KO cells revealed transcriptional remodeling following CDK6 loss resulting in a transition of AML cells toward a monocytic phenotype. Pathway analysis showed that proteasomal function may play a role in BCL2 degradation. Despite these changes, we found that AML cells remain highly dependent on CDK2 and CDK2 inhibition synergizes with venetoclax. Additionally, pharmacologic inhibition of CDK2 showed potent anti-leukemic activity in ven-resistant AML3 cells and in RB1 KO cells which are resistant to CDK4/6 inhibition.

Conclusion: Our study shows that CDK6 mRNA expression is correlated with venetoclax response and BCL2 levels in AML patient samples. Loss of CDK6 leads to a large decrease in BCL2 protein expression and venetoclax resistance, suggesting that targeting CDK4 or CDK2 without targeting CDK6 could be a preferable therapeutic option in AML. We found that CDK6 regulates AML cell state, driving cells towards a monocytic phenotype, known to be resistant to ven treatment. Our data show that AML cells that are resistant to CDK4/6 inhibition are still vulnerable to CDK2 inhibition and that CDK2 inhibitors work synergistically with venetoclax, suggesting a new potential therapeutic vulnerability in AML.

 

 

Melissa Laura Stewart, PhD: No relevant conflicts of interest to declare.